CCR4 and adult T-cell leukemia/lymphoma: This immunotherapy is Mogamulizumab (KW-0761), a defucosylated anti-CCR4 monoclonal antibody, which was approved in 2012 for the treatment of relapsed/refractory ATLL following allogeneic hematopoietic stem cell transplantation, and in 2014 for the treatment of newly diagnosed ATLL patients, in Japan [136,137,138,139,140] (see also [141] in this issue of Cancers).